Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 125Active not recruiting 115Not yet recruiting 21Suspended 16Completed 5Terminated 4Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 2reducing agent and tunicamycin-responsive protein, human 1olutasidenib 1epacadostat 1ebselen 1dexamethasone acetate 1dexamethasone 21-phosphate 1decitabine and cedazuridine drug combination 1daratumumab 1carfilzomib 1auricularum 1Vorinostat 1Surveys and Questionnaires 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Kidney Transplantation 1Immunotherapy, Adoptive 1Immunoglobulin G 1Hyaluronoglucosaminidase 1Fluorodeoxyglucose F18 1Electrochemotherapy 1Dexamethasone 1Continuous Positive Airway Pressure 1Cell- and Tissue-Based Therapy 1Calcium Dobesilate 1Bleomycin 1Biopsy 1A-dmDT390-bisFv(UCHT1) protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Specimen Handling × 30 days × Clear all
NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Roswell Park Cancer Institute

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡